Idorsia Ltd (IDIA.SW)

2,3500 +0,1000 (+4,44%) Ab 01:30PM CEST. Markt geöffnet.

Idorsia Ltd

Hegenheimermattweg 91
Allschwil 4123
Switzerland
41 58 844 10 10
https://www.idorsia.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jean-Paul Clozel M.D.	CEO & Executive Director	856,77k	N/A	1955
Mr. André C. Muller	Executive VP & CFO	N/A	N/A	1963
Dr. Martine Clozel	Executive VP & Chief Scientific Officer	N/A	N/A	1955
Dr. Guy Braunstein M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1956
Mr. Alberto Gimona M.D.	Executive VP & Head of Global Clinical Development	N/A	N/A	1960
Mr. Andrew C. Weiss	Senior VP and Head of Investor Relations & Corporate Communications	N/A	N/A	1968
Mr. Julien Gander L.L.M.	Senior VP, Group General Counsel & Company Secretary	N/A	N/A	1979
Mr. Alexander Khatuntsev	Senior VP & Head of Global Human Resources	N/A	N/A	1978
Mr. Olivier Lambert	Senior VP & Head of Technical Operations	N/A	N/A	1966
Mr. Markus A. Riederer	Senior VP & Head of Drug Discovery Biology	N/A	N/A	1962

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CHF.

Beschreibung

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia. The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Corporate Governance

Idorsia Ltds ISS Governance QualityScore, Stand 1. Mai 2024, lautet 2. Die grundlegenden Scores sind Audit: 10, Vorstand: 2, Shareholderrechte: 1, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.